MYLAN Pharmaceuticals has
announced the US release of
Alfuzosin Hydrochloride Extendedrelease
tablets, which is a generic
version of benign prostatic
hyperplasia treatment Uroxatral.
Urotraxal tablets accounted for
US$241m in sales last year.The above article was sent to subscribers in Pharmacy Daily's issue from 15 Aug 11 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 15 Aug 11
MONTU Group, its subsidiary Alternaleaf Pty Ltd, and their common director Christopher Strauch are facing legal action by the Therapeutic Goods Administration (TGA) in the Federal Court of Australia for alleged unlawful advertising on the effectiveness of their medicinal cannabis products.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.